NCT00442507

Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction

A Phase II Trial of Erlotinib and Avastin in Previously Treated Patients With Cancer of the Esophagus or Gastroesophageal Junction

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Determine the time to progression for the combination of erlotinib and bevacizumab in patients with previously treated metastatic cancer of the esophagus or gastroesophageal junction

Detailed description

We postulate that the addition of bevacizumab may increase the efficacy of erlotinib in patients with metastatic esophageal cancer, without adding significant toxicity. The non-overlapping toxicity profiles may allow the administration of the maximum tolerated doses for both agents without additive toxicities with the goal of demonstrating synergistic clinical activity. This combination has been previously tested in two studies for other malignancies with good tolerance and encouraging results.

Conditions

• Esophageal Neoplasms
• Esophageal Diseases

Interventions

Type	Name	Description
DRUG	Erlotinib
DRUG	Avastin

Timeline

• Start date: 2007-03-01
• Primary completion: 2009-01-01
• Completion: 2009-01-01
• First posted: 2007-03-02
• Last updated: 2015-07-24
• Results posted: 2015-07-03

Locations

1 site across 1 country: United States